Loading…

How Clavulanic Acid Inhibits Serine β‐Lactamases

Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS)...

Full description

Saved in:
Bibliographic Details
Published in:Chembiochem : a European journal of chemical biology 2024-11, Vol.25 (22), p.e202400280-n/a
Main Authors: Lang, Pauline A., Munnik, Mariska, Oluwole, Abraham O., Claridge, Timothy D. W., Robinson, Carol V., Brem, Jürgen, Schofield, Christopher J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3
container_end_page n/a
container_issue 22
container_start_page e202400280
container_title Chembiochem : a European journal of chemical biology
container_volume 25
creator Lang, Pauline A.
Munnik, Mariska
Oluwole, Abraham O.
Claridge, Timothy D. W.
Robinson, Carol V.
Brem, Jürgen
Schofield, Christopher J.
description Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest. Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.
doi_str_mv 10.1002/cbic.202400280
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3084773193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3084773193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3</originalsourceid><addsrcrecordid>eNqFkEFOwzAQRS0EolDYskSR2LBJGXucOFmWCGilSiyAteU4jnCVNCVuqLrjCJyFg3AIToKrliKxYTV_pDd_vj4hZxQGFIBd6dzqAQPG_ZLAHjmiHNNQxIj7W80ZEz1y7NwUANIY6SHpYQoRE3F0RHDULIOsUq9dpWZWB0Nti2A8e7a5XbjgwbR2ZoLPj6-394nSC1UrZ9wJOShV5czpdvbJ0-3NYzYKJ_d342w4CTWLEggLwfwblTMoFM_BC1SojTI8NSASnwB4IbQukxiZNpgLTFkuuFCGRpEosU8uN77ztnnpjFvI2jptKp_UNJ2TCAkXAmmKHr34g06brp35dBIpSxORCFxTgw2l28a51pRy3tpatStJQa7rlOs65a5Of3C-te3y2hQ7_Kc_D6QbYGkrs_rHTmbX4-zX_BuwJoAu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3129878733</pqid></control><display><type>article</type><title>How Clavulanic Acid Inhibits Serine β‐Lactamases</title><source>Wiley</source><creator>Lang, Pauline A. ; Munnik, Mariska ; Oluwole, Abraham O. ; Claridge, Timothy D. W. ; Robinson, Carol V. ; Brem, Jürgen ; Schofield, Christopher J.</creator><creatorcontrib>Lang, Pauline A. ; Munnik, Mariska ; Oluwole, Abraham O. ; Claridge, Timothy D. W. ; Robinson, Carol V. ; Brem, Jürgen ; Schofield, Christopher J.</creatorcontrib><description>Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest. Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.</description><identifier>ISSN: 1439-4227</identifier><identifier>ISSN: 1439-7633</identifier><identifier>EISSN: 1439-7633</identifier><identifier>DOI: 10.1002/cbic.202400280</identifier><identifier>PMID: 39052765</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Acids ; Antimicrobial resistance ; beta-Lactamase Inhibitors - chemical synthesis ; beta-Lactamase Inhibitors - chemistry ; beta-Lactamase Inhibitors - pharmacology ; beta-Lactamases - chemistry ; beta-Lactamases - metabolism ; Clavulanic acid ; Clavulanic Acid - chemistry ; Clavulanic Acid - pharmacology ; Complex formation ; E coli ; Escherichia coli - drug effects ; Escherichia coli - enzymology ; Fragmentation ; In vivo methods and tests ; Mass spectrometry ; Mass spectroscopy ; Mechanism-based inhibition ; Oxazolidine ; Penam sulfone ; Ring opening ; Scaffolds ; Serine ; Serine - chemistry ; Serine - metabolism ; Serine β-lactamase inhibitor ; Sulfones ; β Lactamase</subject><ispartof>Chembiochem : a European journal of chemical biology, 2024-11, Vol.25 (22), p.e202400280-n/a</ispartof><rights>2024 The Authors. ChemBioChem published by Wiley-VCH GmbH</rights><rights>2024 The Authors. ChemBioChem published by Wiley-VCH GmbH.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3</cites><orcidid>0000-0002-0290-6565</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39052765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lang, Pauline A.</creatorcontrib><creatorcontrib>Munnik, Mariska</creatorcontrib><creatorcontrib>Oluwole, Abraham O.</creatorcontrib><creatorcontrib>Claridge, Timothy D. W.</creatorcontrib><creatorcontrib>Robinson, Carol V.</creatorcontrib><creatorcontrib>Brem, Jürgen</creatorcontrib><creatorcontrib>Schofield, Christopher J.</creatorcontrib><title>How Clavulanic Acid Inhibits Serine β‐Lactamases</title><title>Chembiochem : a European journal of chemical biology</title><addtitle>Chembiochem</addtitle><description>Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest. Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.</description><subject>Acids</subject><subject>Antimicrobial resistance</subject><subject>beta-Lactamase Inhibitors - chemical synthesis</subject><subject>beta-Lactamase Inhibitors - chemistry</subject><subject>beta-Lactamase Inhibitors - pharmacology</subject><subject>beta-Lactamases - chemistry</subject><subject>beta-Lactamases - metabolism</subject><subject>Clavulanic acid</subject><subject>Clavulanic Acid - chemistry</subject><subject>Clavulanic Acid - pharmacology</subject><subject>Complex formation</subject><subject>E coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - enzymology</subject><subject>Fragmentation</subject><subject>In vivo methods and tests</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Mechanism-based inhibition</subject><subject>Oxazolidine</subject><subject>Penam sulfone</subject><subject>Ring opening</subject><subject>Scaffolds</subject><subject>Serine</subject><subject>Serine - chemistry</subject><subject>Serine - metabolism</subject><subject>Serine β-lactamase inhibitor</subject><subject>Sulfones</subject><subject>β Lactamase</subject><issn>1439-4227</issn><issn>1439-7633</issn><issn>1439-7633</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNqFkEFOwzAQRS0EolDYskSR2LBJGXucOFmWCGilSiyAteU4jnCVNCVuqLrjCJyFg3AIToKrliKxYTV_pDd_vj4hZxQGFIBd6dzqAQPG_ZLAHjmiHNNQxIj7W80ZEz1y7NwUANIY6SHpYQoRE3F0RHDULIOsUq9dpWZWB0Nti2A8e7a5XbjgwbR2ZoLPj6-394nSC1UrZ9wJOShV5czpdvbJ0-3NYzYKJ_d342w4CTWLEggLwfwblTMoFM_BC1SojTI8NSASnwB4IbQukxiZNpgLTFkuuFCGRpEosU8uN77ztnnpjFvI2jptKp_UNJ2TCAkXAmmKHr34g06brp35dBIpSxORCFxTgw2l28a51pRy3tpatStJQa7rlOs65a5Of3C-te3y2hQ7_Kc_D6QbYGkrs_rHTmbX4-zX_BuwJoAu</recordid><startdate>20241118</startdate><enddate>20241118</enddate><creator>Lang, Pauline A.</creator><creator>Munnik, Mariska</creator><creator>Oluwole, Abraham O.</creator><creator>Claridge, Timothy D. W.</creator><creator>Robinson, Carol V.</creator><creator>Brem, Jürgen</creator><creator>Schofield, Christopher J.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0290-6565</orcidid></search><sort><creationdate>20241118</creationdate><title>How Clavulanic Acid Inhibits Serine β‐Lactamases</title><author>Lang, Pauline A. ; Munnik, Mariska ; Oluwole, Abraham O. ; Claridge, Timothy D. W. ; Robinson, Carol V. ; Brem, Jürgen ; Schofield, Christopher J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Antimicrobial resistance</topic><topic>beta-Lactamase Inhibitors - chemical synthesis</topic><topic>beta-Lactamase Inhibitors - chemistry</topic><topic>beta-Lactamase Inhibitors - pharmacology</topic><topic>beta-Lactamases - chemistry</topic><topic>beta-Lactamases - metabolism</topic><topic>Clavulanic acid</topic><topic>Clavulanic Acid - chemistry</topic><topic>Clavulanic Acid - pharmacology</topic><topic>Complex formation</topic><topic>E coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - enzymology</topic><topic>Fragmentation</topic><topic>In vivo methods and tests</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Mechanism-based inhibition</topic><topic>Oxazolidine</topic><topic>Penam sulfone</topic><topic>Ring opening</topic><topic>Scaffolds</topic><topic>Serine</topic><topic>Serine - chemistry</topic><topic>Serine - metabolism</topic><topic>Serine β-lactamase inhibitor</topic><topic>Sulfones</topic><topic>β Lactamase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lang, Pauline A.</creatorcontrib><creatorcontrib>Munnik, Mariska</creatorcontrib><creatorcontrib>Oluwole, Abraham O.</creatorcontrib><creatorcontrib>Claridge, Timothy D. W.</creatorcontrib><creatorcontrib>Robinson, Carol V.</creatorcontrib><creatorcontrib>Brem, Jürgen</creatorcontrib><creatorcontrib>Schofield, Christopher J.</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley-Blackwell Backfiles (Open access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Chembiochem : a European journal of chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lang, Pauline A.</au><au>Munnik, Mariska</au><au>Oluwole, Abraham O.</au><au>Claridge, Timothy D. W.</au><au>Robinson, Carol V.</au><au>Brem, Jürgen</au><au>Schofield, Christopher J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Clavulanic Acid Inhibits Serine β‐Lactamases</atitle><jtitle>Chembiochem : a European journal of chemical biology</jtitle><addtitle>Chembiochem</addtitle><date>2024-11-18</date><risdate>2024</risdate><volume>25</volume><issue>22</issue><spage>e202400280</spage><epage>n/a</epage><pages>e202400280-n/a</pages><issn>1439-4227</issn><issn>1439-7633</issn><eissn>1439-7633</eissn><abstract>Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest. Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39052765</pmid><doi>10.1002/cbic.202400280</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0290-6565</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1439-4227
ispartof Chembiochem : a European journal of chemical biology, 2024-11, Vol.25 (22), p.e202400280-n/a
issn 1439-4227
1439-7633
1439-7633
language eng
recordid cdi_proquest_miscellaneous_3084773193
source Wiley
subjects Acids
Antimicrobial resistance
beta-Lactamase Inhibitors - chemical synthesis
beta-Lactamase Inhibitors - chemistry
beta-Lactamase Inhibitors - pharmacology
beta-Lactamases - chemistry
beta-Lactamases - metabolism
Clavulanic acid
Clavulanic Acid - chemistry
Clavulanic Acid - pharmacology
Complex formation
E coli
Escherichia coli - drug effects
Escherichia coli - enzymology
Fragmentation
In vivo methods and tests
Mass spectrometry
Mass spectroscopy
Mechanism-based inhibition
Oxazolidine
Penam sulfone
Ring opening
Scaffolds
Serine
Serine - chemistry
Serine - metabolism
Serine β-lactamase inhibitor
Sulfones
β Lactamase
title How Clavulanic Acid Inhibits Serine β‐Lactamases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Clavulanic%20Acid%20Inhibits%20Serine%20%CE%B2%E2%80%90Lactamases&rft.jtitle=Chembiochem%20:%20a%20European%20journal%20of%20chemical%20biology&rft.au=Lang,%20Pauline%20A.&rft.date=2024-11-18&rft.volume=25&rft.issue=22&rft.spage=e202400280&rft.epage=n/a&rft.pages=e202400280-n/a&rft.issn=1439-4227&rft.eissn=1439-7633&rft_id=info:doi/10.1002/cbic.202400280&rft_dat=%3Cproquest_cross%3E3084773193%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3129878733&rft_id=info:pmid/39052765&rfr_iscdi=true